

=> d his nofile

(FILE 'HOME' ENTERED AT 16:58:18 ON 11 JAN 2006)

FILE 'REGISTRY' ENTERED AT 16:58:23 ON 11 JAN 2006

E DKCLA/SQEP

L1 1 SEA ABB=ON (DKCLA)/SQEP

FILE 'REGISTRY' ENTERED AT 16:59:01 ON 11 JAN 2006

D QUE L1

D SQIDE

FILE 'CAPLUS, USPATFULL' ENTERED AT 16:59:19 ON 11 JAN 2006

L2 5 SEA ABB=ON L1

L3 4 DUP REM L2 (1 DUPLICATE REMOVED)

ANSWERS '1-2' FROM FILE CAPLUS

ANSWERS '3-4' FROM FILE USPATFULL

D IBIB ED ABS HITRN 1-4

FILE 'HOME' ENTERED AT 16:59:37 ON 11 JAN 2006

=>

=> fil reg; d que 11  
FILE=REGISTRY ENTERED AT 16:59:01 ON 11 JAN 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 10 JAN 2006 HIGHEST RN 871658-99-0  
DICTIONARY FILE UPDATES: 10 JAN 2006 HIGHEST RN 871658-99-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

~~L1~~ ~~1~~ SEA-FILE=REGISTRY ABB=ON--(DKCLA)/SQEPD

~~=>d-sqide~~


L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 478183=06=1--REGISTRY  
CN L-Alanine, L- $\alpha$ -aspartyl-L-lysyl-L-cysteiny-L-leucyl- (9CI) (CA  
INDEX NAME)  
OTHER NAMES:  
CN 16: PN: US20050013820 SEQID: 16 claimed sequence  
CN 16: PN: WO2009061 SEQID: 16 unclaimed sequence  
FS PROTEIN SEQUENCE; STEREOSEARCH  
SQL 5

PATENT ANNOTATIONS (PNTE):  
Sequence |Patent  
Source |Reference  
=====+=====

Not Given	WO2002099061
	unclaimed

SEQ 1 DKCLA

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

(FILE CAPLUS) ENTERED AT 16:59:19 ON 11 JAN 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

~~(FILE:USPATFULL)~~ ENTERED AT 16:59:19 ON 11 JAN 2006  
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

~~L2~~ 5 ~~L1~~

```
=> dup rem 12
```

PROCESSING COMPLETED FOR L2

~~C~~L3 4 DUP REM L2 (1-DUPLICATE REMOVED)  
ANSWERS '1-2' FROM FILE CAPLUS  
ANSWERS '3-4' FROM FILE USPATFULL

=> ~~d ibib ed abs hitrn 1-4;~~ fil hom

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1  
ACCESSION NUMBER: 2005:58062 CAPLUS  
DOCUMENT NUMBER: 142:129460

TITLE: Calreticulin antagonist for the treatment of  
rheumatoid arthritis  
INVENTOR(S): Holoshitz, Joseph; Ling, Song  
PATENT ASSIGNEE(S): The Regents of the University of Michigan, USA  
SOURCE: U.S. Pat. Appl. Publ., 84 pp., Cont.-in-part of U.S.  
Ser. No. 161,959.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005013820	A1	20050120	US 2004-845407	20040513
US 2003096748	A1	20030522	US 2002-161959	20020603
US 2004236071	A1	20041125	US 2004-786774	20040225
PRIORITY APPLN. INFO.:			US 2002-161959	A2 20020603
			US 2001-295691P	P 20010604

ED Entered STN: 21 Jan 2005

AB The present invention relates to methods and compns. for counteracting and reversing disease-causing signaling defects in disorders with underlying signal transduction aberrations, including but not limited to rheumatoid arthritis.

IT ~~478183-06-1P~~

RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(calreticulin-binding sequence; calreticulin antagonist for treatment of rheumatoid arthritis)

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:946439 CAPLUS

DOCUMENT NUMBER: 138:29107

TITLE: Methods and compositions for the treatment of  
Alzheimer's disease and other diseases associated with  
signal transduction aberrations

INVENTOR(S): Holoshitz, Joseph; Ling, Song  
PATENT ASSIGNEE(S): The Regents of the University of Michigan, USA  
SOURCE: PCT Int. Appl., 97 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent  
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002099061	A2	20021212	WO 2002-US17536	20020604
WO 2002099061	A3	20040226		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003096748	A1	20030522	US 2002-161959	20020603

PRIORITY APPLN. INFO.: US 2001-295691P P 20010604  
US 2002-161959 A 20020603

ED Entered STN: 13 Dec 2002

AB The present invention relates generally to therapeutic methods and compns. More particularly, methods and compns. to counteract and reverse disease-causing signaling defects in diseases with underlying signal transduction aberrations, including but not limited to Alzheimer's disease.

IT ~~478183-06-1~~

RL: PRP (Properties)

(unclaimed sequence; methods and compns. for the treatment of Alzheimer's disease and other diseases associated with signal transduction aberrations)

L3 ANSWER 3 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2004:300201 USPATFULL

TITLE: Methods and compositions for the treatment of diseases associated with signal transduction aberrations

INVENTOR(S): Holoshitz, Joseph, Ann Arbor, MI, UNITED STATES  
Ling, Song, Ypsilanti, MI, UNITED STATES

PATENT ASSIGNEE(S): The Regents Of The University Of Michigan (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004236071	A1	20041125
APPLICATION INFO.:	US 2004-786774	A1	20040225 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-161959, filed on 3 Jun 2002, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Peter G. Carroll, MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94105		
NUMBER OF CLAIMS:	1		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	19 Drawing Page(s)		
LINE COUNT:	3153		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates generally to therapeutic methods and compositions. More particularly, methods and compositions to counteract and reverse disease-causing signaling defects in diseases with underlying signal transduction aberrations, including but not limited to Alzheimer's Disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT ~~478183-06-1~~

(unclaimed sequence; methods and compns. for the treatment of Alzheimer's disease and other diseases associated with signal transduction aberrations)

L3 ANSWER 4 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2003:140906 USPATFULL

TITLE: Methods and compositions for the treatment of diseases associated with signal transduction aberrations

INVENTOR(S): Holoshitz, Joseph, Ann Arbor, MI, UNITED STATES  
Ling, Song, Ann Arbor, MI, UNITED STATES

PATENT ASSIGNEE(S): The Regents Of The University Of Michigan (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2003096748 A1 20030522  
APPLICATION INFO.: US 2002-161959 A1 20020603 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-295691P	20010604 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Peter G. Carroll, MELDEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94105	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	19 Drawing Page(s)	
LINE COUNT:	2986	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates generally to therapeutic methods and compositions. More particularly, methods and compositions to counteract and reverse disease-causing signaling defects in diseases with underlying signal transduction aberrations, including but not limited to Alzheimer's Disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT ~~4781183~~ ~~06219~~  
(unclaimed sequence; methods and compns. for the treatment of Alzheimer's disease and other diseases associated with signal transduction aberrations)

FILE 'HOME' ENTERED AT 16:59:37 ON 11 JAN 2006

=>